Search results
Results from the WOW.Com Content Network
The main goal of diabetes management is to keep blood glucose (BG) levels as normal as possible. [1] If diabetes is not well controlled, further challenges to health may occur. [1] People with diabetes can measure blood sugar by various methods, such as with a BG meter or a continuous glucose monitor, which monitors over several days. [2]
Conventional insulin therapy is characterized by: Insulin injections of a mixture of regular (or rapid) and intermediate acting insulin are performed two times a day, or to improve overnight glucose, mixed in the morning to cover breakfast and lunch, but with regular (or rapid) acting insulin alone for dinner and intermediate acting insulin at bedtime (instead of being mixed in at dinner).
Drugs used in diabetes treat types of diabetes mellitus by decreasing glucose levels in the blood. With the exception of insulin , most GLP-1 receptor agonists ( liraglutide , exenatide , and others), and pramlintide , all diabetes medications are administered orally and are thus called oral hypoglycemic agents or oral antihyperglycemic agents.
GLP-1 drugs for weight loss and type 2 diabetes include dulaglutide, liraglutide, and semaglutide. GIP/GLP-1s. These are dual-acting, meaning they target two receptors in the body: gastric ...
(Reuters) -All doses of Eli Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro are now available, the U.S. Food and Drug Administration's updated shortage list showed on Friday. However ...
Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors.
Self-injected drugs are especially difficult for people with vision or motor difficulties, which are common in people with type 2 diabetes. [29] Attempts to develop an orally bioavailable GLP-1 agonist, either a modified peptide, as in the case of oral semaglutide, [ 37 ] or a small molecule drug, have produced additional drug candidates. [ 28 ]
The long-term study is comparing the long-term benefits and risks of four widely used diabetes drugs in combination with metformin, the most common first-line drug for treating type 2 diabetes. The study will compare drug effects on glucose levels, adverse effects, diabetes complications and quality of life over an average of nearly five years ...